Marco Calabrò, Chiara Fabbri, Siegfried Kasper, Joseph Zohar, Daniel Souery, Stuart Montgomery, Diego Albani, Gianluigi Forloni, Panagiotis Ferentinos, Dan Rujescu, Julien Mendlewicz, Roberto Colombo, Diana De Ronchi, Alessandro Serretti* and Concetta Crisafulli Pages 4296 - 4320 ( 25 )
Background: Major Depressive Disorder(MDD) and its frequent partial response to antidepressants are a major health concern and therefore an important focus of research. Despite the efforts, MDD pathogenesis and the mechanisms of antidepressant action are only partially understood. In the last few years, the need of rethinking the classification of depressive disorders and psychiatric disorders, in general, has been suggested, in order to provide a nosology that reflects more closely the biological background associated with disease pathogenesis and its role/significance in treatment. The classification proposed by the National Institute of Mental Health (NIMH), namely the research domain criteria (RDoC), may represent a key framework to guide research in this direction.
Methods: A literature search was performed on PubMed and Google Scholar databases in order to retrieve data regarding Antidepressants effects on specific RDoC constructs. Further, the targets of drugs of interest were identified through the Drug bank database, and their possible function within RDoC constructs was discussed.
Discussion: In this review, we summarize and discuss the significance of the results of pre-clinical and clinical studies investigating specific RDoC paradigms relevant to depressive phenotypes and antidepressant effects.
Conclusion: The RDoC framework may facilitate a more specific use of antidepressants based on the individual’s spectrum of symptoms and the development of new compounds that target specific depressive symptoms.
Research domain criteria, major depressive disorder, antidepressant, behavioral paradigm, RDoC Constructs, drug targets.
Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Department of Psychiatry and Psychotherapy, Medical University Vienna, Vienna, Department of Psychiatry, Sheba Medical Center, Tel Hashomer, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Laboratoire de Psychologie Medicale, Universite Libre de Bruxelles and Psy Pluriel, Centre Europeen de Psychologie Medicale, Brussels, Imperial College School of Medicine, London, Laboratory of Biology of Neurodegenerative Disorders, Neuroscience Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Laboratory of Biology of Neurodegenerative Disorders, Neuroscience Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Department of Psychiatry, Athens University Medical School, Athens, University Clinic for Psychiatry, Psychotherapy and Psychosomatic, Martin-Luther-University Halle-Wittenberg, Halle, Universite´ Libre de Bruxelles, Brussels, Fondazione Policlinico Universitario “A. Gemelli” - IRCCS, Università Cattolica del Sacro Cuore, Rome, Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina